iECURE included on list of Fierce Biotech’s 2024 Fierce 15
iECURE was recognized for its innovative approach to treating rare childhood diseases by developing therapies that correct gene function directly inside the body.
Penn Spinout Interius BioTherapeutics Raises Additional $67M and doses first patient
The company’s approach focuses on creating cancer-fighting cells directly inside the body, potentially bypassing the need for external cell manipulation and chemotherapy.
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
Carisma has expanded its collaboration with Moderna to develop two chimeric antigen receptor macrophage (CAR-M) targets for autoimmune disease treatment.
Tern Therapeutics Launches with $15 Million in Financing and CLN2 Batten Disease Treatment Pipeline from REGENXBIO
Tern Therapeutics, a biotechnology company focused on developing gene therapies for rare diseases, recently launched with $15 million in financing.
Dr. James Wilson takes on roles in two new companies spun out of Penn’s Gene Therapy Program
James Wilson, MD, PhD, has left Penn after 33 years to take on leadership roles in two independent startups that he co-founded.
Philadelphia Business Journal’s Innovation Sector Celebrates iECURE as PHL Inno’s 2024 Fire Awards Honoree
The Fire Awards aim to celebrate the most promising businesses and individuals driving success and innovation locally in Greater Philadelphia.
President’s Sustainability Prize Winner Shinkei Systems Aims to Upend the Fish-Harvesting Industry
The 2022 President’s Sustainability Prize winner Shinkei Systems was recognized in a recent article by Tech Crunch for its role in changing the seafood industry.
EpiVario Awarded NIH Grant to Advance Research in Treatments for Cocaine Use Disorder
EpiVario is developing neuroepigenetic modulators to treat memory-related addiction and psychiatric disorders.
Interius BioTherapeutics Receives Clearance to Begin Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
Interius intends to begin patient enrollment for the trial in the fourth quarter of 2024.
Development of RNA Therapeutics Targets Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.